Last updated: 2026-09-06 05:39:40. Prices reflect the latest closing data and will resume updating on the next trading day. Stock price data is sourced from Massive.
Krystal Biotech, Inc. (KRYS) operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector and is listed on NASDAQ. The stock is currently priced at $358.39, with a market capitalization of $11.00B and a P/E ratio of 43.91. Over the past 52 weeks, its price has ranged from $136.73 to $382.54. This page covers its latest market performance, valuation, price trends and company information.
$11.00B | |
$365.45 | |
$382.54 | |
$8.03 | |
$371.47 | |
267.35K | |
410.84K | |
43.91 | |
$382.54 | |
$136.73 | |
-- | |
-- |
Krystal Biotech, Inc. (KRYS) last closed at $371.47 as of 2026-09-04 23:56:00, unchanged from the previous close of $371.47.
During the latest regular trading session, KRYS traded between $8.03 and $382.54, with a volume of 267.35K shares. The closing price was near the upper end and near the upper end of its 52-week range.
Over the past seven days, Krystal Biotech, Inc. (KRYS) moved from $357.46 to $358.39, representing a gain of 0.26% ($0.93).
The stock traded between $345.14 and $373.50 during the period. The latest price is near the middle of the 7-day range, indicating range-bound.
The average daily volume was 228.55 thousand shares, down versus the previous seven-day period, indicating lower trading activity.
Position in Range: 90.2%
KRYS is currently trading at $358.39, placing it 90.2% of the way from its 52-week low of $136.73 to its 52-week high of $382.54. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Krystal Biotech Inc is an integrated, commercial-stage biotechnology company focused on the discovery, development, manufacturing, and commercialization of genetic medicines to treat diseases with high unmet medical needs. The company uses its patented HSV-1-based gene therapy platform to create vectors that deliver therapeutic transgenes to target cells. It possesses exclusive rights to develop, manufacture, and commercialize VYJUVEK internationally. The company operates as one operating segment focused on pharmaceutical products and manufactures, markets, and sells VYJUVEK in the United States and markets and sells VYJUVEK in the European Union, and Japan.
| Industry | BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) |
| Employees | 295 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Krystal Biotech, Inc. (KRYS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.